Sherry Pierce

25.1k total citations · 1 hit paper
428 papers, 14.8k citations indexed

About

Sherry Pierce is a scholar working on Hematology, Genetics and Molecular Biology. According to data from OpenAlex, Sherry Pierce has authored 428 papers receiving a total of 14.8k indexed citations (citations by other indexed papers that have themselves been cited), including 356 papers in Hematology, 190 papers in Genetics and 116 papers in Molecular Biology. Recurrent topics in Sherry Pierce's work include Acute Myeloid Leukemia Research (305 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (120 papers) and Chronic Myeloid Leukemia Treatments (107 papers). Sherry Pierce is often cited by papers focused on Acute Myeloid Leukemia Research (305 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (120 papers) and Chronic Myeloid Leukemia Treatments (107 papers). Sherry Pierce collaborates with scholars based in United States, Japan and Spain. Sherry Pierce's co-authors include Hagop M. Kantarjian, Jörge E. Cortes, Elihu H. Estey, Guillermo Garcia‐Manero, Farhad Ravandi, Michael J. Keating, Susan O’Brien, Stefan Faderl, Gautam Borthakur and Elias Jabbour and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Sherry Pierce

415 papers receiving 14.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Results of Treatment With Hyper-CVAD, a Dose-Intensive Regimen, in Adult Acute Lymphocytic Leukemia

2000 586 citations Hagop M. Kantarjian, Jörge E. Cortes et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Sherry Pierce

Since Specialization

Citations

This map shows the geographic impact of Sherry Pierce's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sherry Pierce with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sherry Pierce more than expected).

Fields of papers citing papers by Sherry Pierce

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sherry Pierce. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sherry Pierce. The network helps show where Sherry Pierce may publish in the future.

Co-authorship network of co-authors of Sherry Pierce

This figure shows the co-authorship network connecting the top 25 collaborators of Sherry Pierce. A scholar is included among the top collaborators of Sherry Pierce based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sherry Pierce. Sherry Pierce is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Single-Cell CD4 and CD8 T-Cell Secretome Profiling Reveals Temporal and Niche Differences in Acute Myeloid Leukemia Following Immune Checkpoint Blockade Therapy 2024 ·Cancer Research Communications ·(unknown), (unknown), (unknown), Bofei Wang, Fatima Zahra Jelloul, (unknown), Sean Mackay, Mansour Alfayez, Jairo Matthews, Sherry Pierce, Patrick K. Reville, Naval Daver, Hussein A. Abbas	5
2	FLAG-IDA + venetoclax in newly diagnosed (ND) or relapsed/refractory (RR) AML. 2024 ·Journal of Clinical Oncology ·(unknown), Koichi Takahashi, Sanam Loghavi, Tapan M. Kadia, Naval Daver, Lianchun Xiao, Nicholas J. Short, Gautam Borthakur, Ghayas C. Issa, Naveen Pemmaraju, Patrick K. Reville, Guillermo Montalban‐Bravo, Musa Yılmaz, Guillermo Garcia‐Manero, Farhad Ravandi‐Kashani, Marina Konopleva, (unknown), Sherry Pierce, Hagop M. Kantarjian, Courtney D. DiNardo	8
3	A phase I study of the myeloid cell leukemia 1 (MCL1) inhibitor tapotoclax (AMG 176) in patients with myelodysplastic syndromes after hypomethylating agent failure. 2024 ·Journal of Clinical Oncology ·Kelly S. Chien, Juan José Rodríguez‐Sevilla, (unknown), Guillermo Montalban‐Bravo, Danielle Hammond, Mahesh Swaminathan, Alexandre Bazinet, (unknown), (unknown), Heather Schneider, (unknown), Sherry Pierce, Xuelin Huang, Elias Jabbour, Hagop M. Kantarjian, Guillermo Garcia‐Manero	1
4	Venetoclax abrogates the prognostic impact of splicing factor gene mutations in newly diagnosed acute myeloid leukemia 2023 ·Blood ·Jayastu Senapati, (unknown), Sanam Loghavi, Nicholas J. Short, Ghayas C. Issa, Abhishek Maiti, Hussein A. Abbas, Naval Daver, Naveen Pemmaraju, Sherry Pierce, Kelly S. Chien, Koji Sasaki, Tapan M. Kadia, Danielle Hammond, Gautam Borthakur, Keyur P. Patel, Farhad Ravandi, Hagop M. Kantarjian, Guillermo Garcia‐Manero, Courtney D. DiNardo	35
5	The outcomes of patients with chronic myeloid leukemia treated with third‐line BCR::ABL1 tyrosine kinase inhibitors 2023 ·American Journal of Hematology ·Elias Jabbour, Koji Sasaki, Fadi Haddad, Ghayas C. Issa, Guillermo Garcia‐Manero, Tapan M. Kadia, Nitin Jain, Musa Yılmaz, Courtney D. DiNardo, Keyur P. Patel, Rashmi Kanagal‐Shamanna, Richard Champlin, Issa F. Khouri, Sara Dellasala, Sherry Pierce, Hagop M. Kantarjian	15
6	Retrospective comparison of survival and responses to Fludarabine, Cytarabine, GCSF (FLAG) in combination with gemtuzumab ozogamicin (GO) or Idarubicin (IDA) in patients with newly diagnosed core binding factor (CBF) acute myelogenous leukemia: MD Anderson experience in 174 patients 2022 ·American Journal of Hematology ·Gautam Borthakur, Farhad Ravandi, Keyur P. Patel, Xuemei Wang, Tapan M. Kadia, Courtney D. DiNardo, Guillermo Garcia‐Manero, Naveen Pemmaraju, Elias Jabbour, Koichi Takahashi, Maro Ohanian, Naval Daver, Yesid Alvarado, Mark Brandt, Sherry Pierce, Hagop M. Kantarjian	20
7	Implications of RAS mutational status in subsets of patients with newly diagnosed acute myeloid leukemia across therapy subtypes 2022 ·American Journal of Hematology ·(unknown), Kunhwa Kim, Rashmi Kanagal‐Shamanna, Gautam Borthakur, Guillermo Montalban‐Bravo, Naval Daver, Courtney D. DiNardo, Nicholas J. Short, Musa Yılmaz, Naveen Pemmaraju, Koichi Takahashi, Elias Jabbour, Sherry Pierce, Marina Konopleva, Kapil N. Bhalla, Guillermo Garcia‐Manero, Farhad Ravandi, Hagop M. Kantarjian, Tapan M. Kadia	17
8	Improved outcomes among newly diagnosed patients with FMS‐like tyrosine kinase 3 internal tandem duplication mutated acute myeloid leukemia treated with contemporary therapy: Revisiting the European LeukemiaNet adverse risk classification 2022 ·American Journal of Hematology ·Patrick K. Reville, Koji Sasaki, Hagop M. Kantarjian, Naval Daver, Musa Yılmaz, Courtney D. DiNardo, Nicholas J. Short, Gautam Borthakur, Naveen Pemmaraju, Rohtesh S. Mehta, Sherry Pierce, Sergej Konoplev, Joseph D. Khoury, Guillermo Garcia‐Manero, Marina Konopleva, Elias Jabbour, Farhad Ravandi, Tapan M. Kadia	16
9	Urgent cytoreduction for newly diagnosed acute myeloid leukemia patients allows acquisition of pretreatment genomic data and enrollment on investigational clinical trials 2022 ·American Journal of Hematology ·Kunhwa Kim, Marina Konopleva, Courtney D. DiNardo, Gautam Borthakur, Sanam Loghavi, Guilin Tang, Naval Daver, Naveen Pemmaraju, Elias Jabbour, Caitlin R. Rausch, Musa Yılmaz, Koji Sasaki, Nicholas J. Short, Nitin Jain, Mark Brandt, Sherry Pierce, Guillermo Garcia‐Manero, Farhad Ravandi, Hagop M. Kantarjian, Tapan M. Kadia	6
10	Clinical Characteristics and Contemporary Outcomes of Acute Myeloid Leukemia Evolving from Chronic Myelomonocytic Leukemia 2021 ·Blood ·Danielle Hammond, Tapan M. Kadia, Courtney D. DiNardo, Marina Konopleva, Nicholas J. Short, Naval Daver, Farhad Ravandi, Naveen Pemmaraju, Elias Jabbour, Kelly S. Chien, Sherry Pierce, Hagop M. Kantarjian, Guillermo Garcia‐Manero, Guillermo Montalban‐Bravo	1
11	Prognostic value of blasts in peripheral blood in myelofibrosis in the ruxolitinib era 2020 ·Cancer ·Lucia Masárová, Prithviraj Bose, Naveen Pemmaraju, Naval Daver, Lingsha Zhou, Sherry Pierce, Koji Sasaki, Hagop M. Kantarjian, Zeev Estrov, Srđan Verstovšek	18
12	Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3‐internal tandem duplication mutation–positive acute myeloid leukemia 2019 ·Cancer ·Koji Sasaki, Hagop M. Kantarjian, Tapan M. Kadia, Keyur P. Patel, Sanam Loghavi, Guillermo Garcia‐Manero, Elias Jabbour, Courtney D. DiNardo, Naveen Pemmaraju, Naval Daver, Iman Abou Dalle, Nicholas J. Short, Musa Yılmaz, Prithviraj Bose, Kiran Naqvi, Sherry Pierce, Fevzi Yalniz, Jörge E. Cortes, Farhad Ravandi	36
13	Validation of the 2017 revision of the WHO chronic myelomonocytic leukemia categories 2018 ·Blood Advances ·Sanam Loghavi, Dawen Sui, Peng Wei, Guillermo Garcia‐Manero, Sherry Pierce, Mark J. Routbort, Elias Jabbour, Naveen Pemmaraju, Rashmi Kanagal‐Shamanna, (unknown), Shimin Hu, Zhuang Zuo, L. Jeffrey Medeiros, Hagop M. Kantarjian, Joseph D. Khoury	29
14	Validation of the 2017 European LeukemiaNet classification for acute myeloid leukemia with NPM1 and FLT3 ‐internal tandem duplication genotypes 2018 ·Cancer ·Prajwal Boddu, Tapan M. Kadia, Guillermo Garcia‐Manero, Jörge E. Cortes, Mansour Alfayez, Gautam Borthakur, Marina Konopleva, Elias Jabbour, Naval Daver, Courtney D. DiNardo, Kiran Naqvi, Musa Yılmaz, Nicholas J. Short, Sherry Pierce, Hagop M. Kantarjian, Farhad Ravandi	37
15	Outcomes of Patients With Relapsed Core Binding Factor-Positive Acute Myeloid Leukemia 2017 ·Clinical Lymphoma Myeloma & Leukemia ·Maliha Khan, Jörge E. Cortes, Wei Qiao, (unknown), Sherry Pierce, Farhad Ravandi, Hagop M. Kantarjian, Gautam Borthakur	12
16	Prediction for sustained deep molecular response of BCR‐ABL1 levels in patients with chronic myeloid leukemia in chronic phase 2017 ·Cancer ·Koji Sasaki, Hagop M. Kantarjian, Susan O’Brien, Farhad Ravandi, Marina Konopleva, Gautam Borthakur, Guillermo Garcia‐Manero, William G. Wierda, Naval Daver, Alessandra Ferrajoli, Koichi Takahashi, Preetesh Jain, Mary Beth Rios, Sherry Pierce, Elias Jabbour, Jörge E. Cortes	23
17	Post-Transplant Cyclophosphamide Improves Progression Free Survival after Allogeneic Hematopoietic Stem Cell Transplantation in AML/MDS Patients with Prior CTLA-4 or PD-1 Blockade 2017 ·Blood ·Betül Oran, Guillermo Garcia‐Manero, Rima M. Saliba, Gheath Alatrash, Elias Jabbour, Uday Popat, Farhad Ravandi, Amin M. Alousi, Tapan M. Kadia, Marina Konopleva, Courtney D. DiNardo, Sherry Pierce, Katy Rezvani, Elizabeth J. Shpall, Padmanee Sharma, Richard E. Champlin, Hagop M. Kantarjian, Naval Daver	1
18	Survival Impact of Patients (Pts) with Chronic Myeloid Leukemia (CML) Due to Failure from the Use of One or More Tyrosine Kinase Inhibitors (TKI) 2015 ·Blood ·(unknown), Sherry Pierce, Mark Brandt, Srđan Verstovšek, Gautam Borthakur, Hagop M. Kantarjian, Farhad Ravandi, William G. Wierda, Guillermo Garcia‐Manero, Naval Daver, Tapan M. Kadia, Jan A. Burger, Naveen Pemmaraju, Elias Jabbour, Jörge E. Cortes	4
19	Prediction of Early Death After Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia With Pretreatment Risk Scores: A Novel Paradigm for Treatment Assignment 2011 ·Journal of Clinical Oncology ·Roland B. Walter, Megan Othus, Gautam Borthakur, Farhad Ravandi, Jörge E. Cortes, Sherry Pierce, Frederick R. Appelbaum, Hagop Kantarjian, Elihu H. Estey	244
20	Randomized Comparison of Cooked and Noncooked Diets in Patients Undergoing Remission Induction Therapy for Acute Myeloid Leukemia 2008 ·Journal of Clinical Oncology ·Alison Gardner, Gloria Mattiuzzi, Stefan Faderl, Gautam Borthakur, Guillermo Garcia‐Manero, Sherry Pierce, Mark Brandt, Elihu H. Estey	84

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact